No profile data available.
Abrdn Life Sciences Investors (HQL) is a financial services company in the multi-strategy investment services industry, based in Philadelphia, United States.
It reported revenue of $86.39 million for fiscal year 2025, down 0.3% from fiscal year 2024, and net income of $85.59 million. Its market capitalization was $551.91 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended September 30, 2025; market data as of October 9, 2026.
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe.
Abrdn Life Sciences Investors reported $86.39 million in revenue for fiscal year 2025, down 0.3% from $86.69 million in fiscal year 2024.
$551.91 million as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-strategy investment services) include Cohen & Steers Limited Duration Preferred and Income Fund, Inc. (LDP), Royce Micro-Cap Trust, Inc. (RMT), Eaton Vance Risk-Managed Diversified Equity Income Fund (ETJ), Abrdn Income Credit Strategies Fund (ACP).